EFFICACY OF MIDOSTAURINE IN ACUTE MYELOID LEUKEMIA WITH FLT-3 MUTATION

Main Article Content

Egamova Sitora Kabilovna

Abstract

Detection of FLT3-ITD mutation in patients with acute myeloid leukemia (AML) is associated with a poor prognosis and is an indication to transplantation of allogeneic hematopoietic stem cells in the first remission. Midostaurin is the first FLT3 inhibitor approved ny for the treatment of patients with AML with FLT3 mutation.

Downloads

Download data is not yet available.

Article Details

How to Cite
Egamova Sitora Kabilovna. (2022). EFFICACY OF MIDOSTAURINE IN ACUTE MYELOID LEUKEMIA WITH FLT-3 MUTATION. International Journal of Innovations in Engineering Research and Technology, 9(9), 9-11. https://doi.org/10.17605/OSF.IO/DPZGA
Section
Articles

How to Cite

Egamova Sitora Kabilovna. (2022). EFFICACY OF MIDOSTAURINE IN ACUTE MYELOID LEUKEMIA WITH FLT-3 MUTATION. International Journal of Innovations in Engineering Research and Technology, 9(9), 9-11. https://doi.org/10.17605/OSF.IO/DPZGA

Similar Articles

You may also start an advanced similarity search for this article.